How GLP-1 agonists are transforming metabolic health with minimal dosing
Semaglutide and tirzepatide have become some of the most discussed medications in medicine. Here's what you need to know about how they work, who they're for, and how we use them at Primal Mountain Medical.
Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) have become some of the most discussed medications in medicine over the past several years. The clinical results have been remarkable — but there's a lot of noise, misinformation, and misuse in the market. Here's what you need to know.
Both medications are GLP-1 receptor agonists — they mimic glucagon-like peptide-1, a hormone naturally produced in the gut after eating. GLP-1 signals the brain to reduce appetite, slows gastric emptying (so you feel full longer), and improves insulin sensitivity.
Tirzepatide goes a step further — it's a dual GIP/GLP-1 agonist, meaning it activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. This dual mechanism makes it more effective for both weight loss and glucose control than semaglutide alone.
The clinical trial data is impressive:
At Primal Mountain Medical, we use a minimal effective dose approach — starting low and titrating slowly to achieve results while minimizing side effects. The most common side effects (nausea, GI discomfort) are almost entirely dose-dependent and can be avoided with careful titration.
This approach also reduces cost and long-term dependency concerns.
NOT SURE WHERE TO START?
A $49 lab panel gives you the numbers. A free consultation gives you the plan. Most men start with labs — but if you already know something's off, skip straight to talking with our team.
These medications may be appropriate for:
They are not appropriate for patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
These medications are tools, not solutions. The best outcomes occur when they're combined with:
At Primal Mountain Medical, every peptide protocol includes health coaching to ensure patients build the habits that will sustain their results long-term.
If you're interested in learning whether semaglutide or tirzepatide might be right for you, the first step is a comprehensive evaluation including labs, health history, and a consultation with our medical team.
Take the Free Hormone Quiz or call 1-866-913-2828 to schedule a consultation.
Semaglutide (Ozempic, Wegovy) is a single-receptor GLP-1 agonist. Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 agonist — it activates two gut-hormone receptors instead of one. Clinical trials show semaglutide produces 15–17% body-weight loss on average at maximum dose; tirzepatide produces 20–22%. Tirzepatide tends to have a smoother side-effect profile at equivalent efficacy for many patients.
The most common side effects are gastrointestinal — nausea, constipation, reflux, and occasional diarrhea — and they are almost entirely dose-dependent. A slow titration schedule at the minimal effective dose dramatically reduces side effects. Less common but more serious concerns include pancreatitis, gallbladder issues, and muscle loss if patients underconsume protein or skip resistance training. Physician-supervised monitoring mitigates all of these.
Brand-name GLP-1 medications (Wegovy, Zepbound, Ozempic, Mounjaro) typically cost $900–$1,400 per month without insurance coverage. Compounded formulations obtained through licensed pharmacies and prescribed by a physician are substantially more affordable and allow for the minimal-effective-dose approach we use clinically. The exact monthly cost depends on dose, titration schedule, and pharmacy.
GLP-1 therapy is best viewed as a medium-term metabolic intervention, not a permanent medication. Many patients use it for 6–18 months to reach a target body composition, then transition to a maintenance protocol — often a lower dose or intermittent dosing — paired with ongoing resistance training and nutrition coaching. Some patients come off entirely; others benefit from long-term low-dose maintenance. The decision is individualized.
Not if the protocol is built correctly. Studies show that without protein and resistance training, 20–40% of weight lost on GLP-1 therapy is lean tissue. Our protocols pair every GLP-1 prescription with a protein target of 0.7–1 g per pound of goal body weight, a structured resistance training plan, and regular body-composition tracking to protect muscle. See our [men's GLP-1 muscle-preservation guide](/blog/glp1-weight-loss-for-men) for the full protocol. Done correctly, GLP-1 weight loss is primarily fat loss.
Peptide protocols start with bloodwork. See where your IGF-1, hormones, and metabolic markers stand — or talk with our team about the right peptide for your goals.